Recombinant human growth hormone for treating burns and donor sites.

What It Covers

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a meta-analysis.

To determine the effects of rhGH on the healing rate of burn wounds and donor sites in people with burns.

Why It Was Studied

This change in protein metabolism correlates with poor wound healing of the burn and donor sites.

Randomised controlled trials (RCTs) comparing rhGH with any comparator intervention, e.g. oxandrolone or placebo, in adults or children with burns.

Who the Included Studies Covered

PubMed indexes the participants as infants, young children, children, teenagers, young adults, adults, middle-aged adults and older adults.

How the Review Was Done

The researchers searched the Cochrane Wounds Group Specialised Register (searched 28 June 2012); The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 6); Database of Abstracts of Reviews of Effects (DARE) (The Cochrane Library 2011, Issue 3); Ovid MEDLINE (1950 to June Week 3 2012); Ovid MEDLINE (In-Process & Other Non-Indexed Citations June 27, 2012); Ovid EMBASE (1980 to 2012 Week 25); and EBSCO CINAHL (1982 to 21 June 2012).

What Was Measured

Two review authors independently selected studies, assessed trial quality and extracted data.

The primary outcomes were the healing of the burn wound and donor sites and the occurrence of wound infections.

PubMed files the paper under topics including Anabolic Agents, Body Surface Area, Burns, Human Growth Hormone, Oxandrolone, Randomized Controlled Trials as Topic and Recombinant Proteins.

What This Means in Plain Language

This is a meta-analysis of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 12 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2012 (The Cochrane database of systematic reviews), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.